A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas
Phase of Trial: Phase II
Latest Information Update: 02 May 2018
At a glance
- Drugs Palovarotene (Primary)
- Indications Bone disorders
- Focus Therapeutic Use
- Acronyms MO-Ped
- Sponsors Clementia Pharmaceuticals
- 20 Apr 2018 According to a Clementia Pharmaceuticals media release, 12-month interim data readout is anticipated in the first half of 2020, with 24-month top-line results in the first half of 2021.
- 22 Mar 2018 Status changed from not yet recruiting to recruiting.
- 05 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Mar 2018.